"I love going to health care conferences, where companies often reveal new technologies, groundbreaking drugs, or novel ways of attacking diseases," says Marc Lichtenfeld.

The contributing editor to Investment U explains, "Here's a review of four interesting presentations I recently saw at LifeTech Capital's small-cap health care conference in Miami: Inovio Pharmaceuticals (INO), Nabi Pharmaceuticals (NABI), NeoStem (NBS), and Oculus Innovative Sciences (OCLS).

Mattress maker Sealy (ZZ) wasn't one of my favorite stocks last year. I wasn't too bullish on the company back in the summertime. Of course, the stock rallies after I render my bearish opinion. Always happens, right? It's okay. I felt the risk at the time wasn't worth it. I did allow, however, the opportunity for checking in on the fundamentals at a later date.

Well, we are now at a later date, so let's check out the Q4 numbers, which were released to Wall Street on Wednesday after the bell. Overall sales increased a little less than 2%. Domestic revenues were better than international revenues (and, no, the latter wasn't helped out even with the elimination of currency effects).

Sealy (NYSE: ZZ) is another one of those cheap stocks that's up big from lows achieved earlier in the year. When I say cheap, I don't mean value. I'm talking about a low-priced equity. The kind of equity that is priced below $5 per share. In the case of Sealy, its shares could be had, as of the close of trading on Tuesday, for $1.96.

But wait, you could have gotten it even cheaper in the after-hours session, because shares of the bedding manufacturer traded down to $1.82 on its Q2 report. I have to agree with the market. Although there were some positive elements contained in the release, overall, I wasn't impressed enough by the numbers to become a buyer.

This post is part of a 12-article feature on the best bets for investing in China. To see all the other recommendations in this special report, click here.

"One Chinese sector being relatively ignored by Wall Street is the biotech industry," notes Keith Fitz-Gerald. In The New China Trader, he looks to a biotech speculation -- Sinovac (AMEX: SVA).

"The government knows that the wheels could fall off the bike rather quickly if average Chinese citizens begin to see a dramatic reversal in their health and happiness.

"If you are looking for maximum rebound potential, you have to go lower down on the quality spectrum; it is typically the lower quality and lower priced stocks that will have the largest gains when the market rebounds," says turnaround expert George Putnam.

In his industry-leading service focused on distressed companies, The Turnround Letter, he looks at a package of 10 stocks recently trading below $5 per share while also offering "bundles of cash."

Here's his review: